Loading...
Market
What will be the total revenue from Zepbound under Medicare Part D by end of 2025?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Financial reports from Eli Lilly or CMS data
Story
Medicare Part D to Cover Eli Lilly’s Zepbound for Sleep Apnea Treatment Following FDA Approval, Creating Opportunity for $LLY
Jan 9, 2025, 02:31 PM
The Centers for Medicare & Medicaid Services (CMS) has announced that Medicare will now cover Eli Lilly's Zepbound for the treatment of obstructive sleep apnea (OSA). This decision follows the drug's recent approval by the FDA, making Zepbound the first medication specifically designed for moderate-to-severe OSA. The coverage under Medicare Part D plans presents a substantial opportunity for Eli Lilly, as it could lead to increased diagnoses and treatment of sleep apnea among patients. However, reports indicate that the costs associated with this coverage could be significant for some patients.
View original story
Similar markets
$1 billion to $2 billion • 25%
Less than $1 billion • 25%
More than $3 billion • 25%
$2 billion to $3 billion • 25%
More than 300,000 • 25%
100,000 to 200,000 • 25%
Less than 100,000 • 25%
200,000 to 300,000 • 25%
Stock price increases by more than 15% • 25%
Stock price increases by 10% to 15% • 25%
Stock price increases by 5% to 10% • 25%
Stock price increases by less than 5% • 25%
Less than 100,000 • 25%
200,001 to 300,000 • 25%
More than 300,000 • 25%
100,000 to 200,000 • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
No • 50%
Yes • 50%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
Less than $5 billion • 25%
More than $15 billion • 25%
No • 50%
Yes • 50%
20% to 30% • 25%
10% to 20% • 25%
More than 30% • 25%
Less than 10% • 25%